Semaglutide peptide vs Ozempic: what you're actually comparing

You've found 'semaglutide peptide' for sale and want to know if it's the same thing

Here's the scenario: you've searched around, you've seen peptide suppliers listing semaglutide alongside BPC-157 and other research chemicals, and you're wondering whether this is simply Ozempic or Wegovy under a different name, available without the clinic visit. It's a reasonable question, and it deserves a straight answer.

Semaglutide is a GLP-1 receptor agonist, a synthetic peptide that mimics a gut hormone involved in appetite regulation and blood-sugar control. In that sense, yes, all three terms (semaglutide peptide, Ozempic, Wegovy) refer to the same active molecule. But the molecule alone tells you almost nothing about whether a product is safe, correctly dosed, sterile or legal to use. The difference between licensed semaglutide and research-grade peptides comes down to manufacturing standards, MHRA oversight and clinical accountability, none of which apply to peptide suppliers.

Research peptide semaglutide is sold for laboratory use. It is not manufactured to the standards required for human injection, has no patient information leaflet, no verified concentration and no prescriber oversight. The MHRA has warned repeatedly about fake and unlicensed weight-loss products circulating online, in one operation, around 20 million doses of illegally traded weight-loss medicines were seized. That's not a niche enforcement action; it's the scale of the problem. You can report suspect sellers at the MHRA's Yellow Card portal.

Where Ozempic actually sits in UK law, and why it isn't a weight-loss medicine

Ozempic is semaglutide, manufactured by Novo Nordisk and licensed in the UK specifically for type 2 diabetes. It is a prescription-only medicine. At no point has it held a UK licence for weight management. The MHRA is clear on this: the NHS semaglutide pages distinguish between the diabetes indication (Ozempic, Rybelsus) and the weight-management indication (Wegovy) because they are different licensed products, even though the molecule is identical.

Prescribing Ozempic off-label for weight loss is technically possible in the UK, but it is not standard practice, not what NICE recommends, and not what any responsible online pharmacy would do routinely. If you come across a service offering Ozempic for weight loss without any explanation of the licensing position, that's worth treating as a red flag.

The comparison of Ozempic and semaglutide for weight loss is essentially a question about licensing, not pharmacology. The pharmacology is the same. The legal and clinical status is very different. For a detailed breakdown of how they sit side by side, this page walks through the distinction directly.

What's actually licensed for weight loss in the UK, and what the evidence shows

Two medicines are licensed for weight management in the UK that our prescribers work with: Wegovy (semaglutide 2.4mg, and now up to 7.2mg) and Mounjaro (tirzepatide). For semaglutide specifically, the licensed weight-loss pathway is Wegovy.

The evidence behind it is substantial. The STEP 1 trial (published in the New England Journal of Medicine) found an average body-weight reduction of around 15% over 68 weeks in adults using semaglutide 2.4mg alongside lifestyle changes. In January 2026 the MHRA approved a 7.2mg maintenance dose, and a dedicated single-dose 7.2mg pen followed in April 2026, with trial data reporting around 20.7% average weight loss over 72 weeks at that dose. These are peer-reviewed, MHRA-assessed outcomes, not a peptide supplier's product description.

NICE recommends semaglutide (Wegovy) for use in specialist weight management services for eligible adults, for up to two years. NICE's full appraisal (TA875) sets out the eligibility criteria in detail. A prescriber assesses whether you meet them, BMI alone isn't the whole picture.

A quick comparison: what each product is actually approved for

If you're weighing Wegovy against Ozempic) or trying to understand whether semaglutide performs better in one form than another, the licensing question has to come first. Which licensed treatment suits your health picture is a clinical decision our prescribers work through with you. There is no shortcut that skips that step and keeps you safe.

If you'd like to explore what treatment is available for your circumstances, start a free consultation and a GPhC-registered prescriber will review your answers personally. Your medication, if approved, arrives the next working day via DPD, tracked, in plain packaging, nothing on the outside to say what's inside.